Madrigal Pharmaceuticals entered an exclusive global license agreement for SYH2086, a potential best-in-class MASH treatment.
1 report, 1 independent
Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Madrigal Pharmaceuticals entered an exclusive global license agreement for SYH2086, a potential best-in-class MASH treatment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Madrigal Pharmaceuticals (United States)
company in West Conshohocken, United States
-
Mash
Japanese singer-songwriter
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireMadrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited License agreement supports Madrigal’s pipeline strategy